Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.40 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | PRF1 | P14222 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724184 | 0.85 | PARP10 (0.56) | GRM5PARP10PARP11 | |
| SCHEMBL162956 | 0.83 | CLK4 (0.49) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL26695991 | 0.76 | PRF1 (0.46) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL7901539 | 0.73 | CLK4 (0.49) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL18786847 | 0.71 | MKNK1 (0.52) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL148819 | 0.71 | PARP10 (0.68) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL9513168 | 0.71 | CYP1A2 (0.46) | IGLV6-57MEN1ALDH1A1MAPTHPGD | |
| SCHEMBL20430099 | 0.70 | CLK4 (0.51) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL18939828 | 0.70 | CLK4 (0.46) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL18199110 | 0.70 | KDM4E (0.38) | IGLV6-57PARP10PARP11ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975260-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975260-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975260-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2611798-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| CN-103201277-A | Pyridazinones, method of making, and method of use thereof | GILEAD CONNECTICUT INC | 2013-07-10 | — | — | CN | disclosed |
| WO-2012030990-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030990-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, TYK2, LCK | CLK4 266/4885DAPK3 190/4885NTRK1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.